Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.
Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Thromb Haemost. 2022 Oct;122(10):1723-1731. doi: 10.1055/s-0042-1750327. Epub 2022 Jul 4.
An accurate point-of-care test for detecting effective anticoagulation by direct oral anticoagulants (DOACs) in emergencies is an unmet need. We investigated the accuracy of a urinary qualitative strip test (DOAC Dipstick) to detect relevant DOAC exposure in patients who presented to an emergency department. In this prospective single-center cohort-type cross-sectional study, adults on DOAC treatment were enrolled. We assessed clinical sensitivity and specificity of DOAC Dipstick factor Xa and thrombin inhibitor pads to detect DOAC plasma levels ≥30 ng/mL using urine samples as the testing matrix. Liquid chromatography coupled with tandem-mass spectrometry was used as the reference standard method for plasma and urine measurement of DOAC concentrations. Of 293 patients enrolled, 265 patients were included in the analysis, of whom 92 were treated with rivaroxaban, 65 with apixaban, 77 with edoxaban, and 31 with dabigatran. The clinical sensitivity and specificity of the dipstick on urine samples to detect ≥30 ng/mL dabigatran plasma levels were 100% (95% confidence interval [CI]: 87-100%) and 98% (95% CI: 95-99%), respectively. The sensitivity and specificity of the dipstick to detect ≥30 ng/mL factor Xa inhibitor plasma levels were 97% (95% CI: 94-99%) and 69% (95% CI: 56-79%), respectively. The DOAC Dipstick sensitively identified effective thrombin and factor Xa inhibition in a real-world cohort of patients presenting at an emergency department. Therefore, the dipstick might provide a valuable test to detect relevant DOAC exposure in emergencies, although further studies will be needed to confirm these findings.
在急诊情况下,一种准确的即时检测方法来检测直接口服抗凝剂(DOAC)的抗凝效果是未满足的需求。我们研究了尿液定性条带检测(DOAC 试条)检测来急诊就诊的接受 DOAC 治疗的患者中是否存在相关 DOAC 暴露的准确性。在这项前瞻性单中心队列型横断面研究中,纳入了正在接受 DOAC 治疗的成年人。我们评估了 DOAC 试条因子 Xa 和凝血酶抑制剂垫的临床敏感性和特异性,以检测尿液样本中 DOAC 血浆水平≥30ng/ml。液相色谱串联质谱法被用作 DOAC 浓度的血浆和尿液测量的参考标准方法。在纳入的 293 名患者中,265 名患者被纳入分析,其中 92 名接受利伐沙班治疗,65 名接受阿哌沙班治疗,77 名接受依度沙班治疗,31 名接受达比加群治疗。试条在检测尿液样本中≥30ng/ml达比加群血浆水平的临床敏感性和特异性分别为 100%(95%置信区间[CI]:87-100%)和 98%(95%CI:95-99%)。试条检测因子 Xa 抑制剂血浆水平≥30ng/ml 的敏感性和特异性分别为 97%(95%CI:94-99%)和 69%(95%CI:56-79%)。DOAC 试条在真实世界的来急诊就诊的患者队列中灵敏地识别了有效的凝血酶和因子 Xa 抑制。因此,尽管需要进一步的研究来证实这些发现,但试条可能提供一种有价值的检测方法来检测急诊中的相关 DOAC 暴露。